12-1979-42

antibody from Invitrogen Antibodies

Targeting: CCR7 BLR2, CD197, CDw197, CMKBR7, EBI1

Provider product page for 12-1979-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [21]
Comments [0]
Validations
Flow cytometry [1]
Other assay [10]

Submit

Product number: 12-1979-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD197 (CCR7) Monoclonal Antibody (3D12), PE, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The 3D12 monoclonal antibody reacts with human CCR7, also known as EBI-1 and CD197. CCR7 is a member of the G-protein-coupled chemokine receptor family with seven membrane-spanning domains and functions as a receptor for 6Ckine/SLC (secondary lymphoid-tissue chemokine), CCL19 and CCL21. CCR7 has been shown to be internalized via clathrin-coated pits and the majority recycled back to the plasma membrane. CCR7 is expressed on T cells and can be used to distinguish populations of naive from central and effector memory T cells. CCR7 has been shown to play a role in migration of memory T cells to inflamed tissue. Expression of CCR7 is also found on DC's. During DC maturation CCR7 expression increases and is thought to be involved in a variety of functions: chemotaxis to the lymph node, cellular architecture, rate of endocytosis, survival and maturation. Expression of CCR7 on the cell surface can be down regulated upon ligand binding.
Conjugate: Yellow dye
Antibody clone number: 3D12
Concentration: 5 µL/Test

CCR7 protein structure - 12-1979-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. Expression levels of chemokine receptors on CIK cells generated from patients with CRC and healthy donors. (A) Analysis of the expression levels of CCR4, CCR5, CCR7, CXCR3 and CXCR4 on CIK cells via flow cytometry revealed that CXCR3 and CXCR4 had higher expression levels on CIK cells compared with isotype, expression profiles of CCR4, CCR5 and CCR7 did not show significant changes compared with isotype. (B) Dynamic changes of chemokine receptors CCR4, CCR5, CCR7, CXCR3 and CXCR4 of CIK cells on D7, 14, 21 and 28 were detected in patients with CRC and HD CIK cells via flow cytometry. The result revealed that expression levels of CXCR3 and CXCR4 were significantly higher on CIK cells cultured from CRC compared with HD at all the time points analyzed, while the expression levels of CCR4, CCR5 and CCR7 were significantly higher on CIK cells cultured from CRC compared with HD at different time points analyzed (CCR4 on D7 and D28; CCR5 on D28; CCR7 on D7, D21 and D28). All comparisons were performed using unpaired Student''s t-test with Welch''s correction. *P
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Paclitaxel dysregulates CD4 + and CD8 + T-cell subpopulations in an eIF4E-dependent manner. (A) Gating strategy used for flow cytometry of lymphocytes from popliteal and inguinal lymph nodes. T-cells were separated from the whole lymphoid cells population using CD3. CD3 + cells were then gated for CD4 + T-cell and CD8 + T-cells. For each of these subsets, cells were further gated for CCR7 or CD25 and CD44. (B) Quantification of CD4 + T-cells from the CD3 population from male mice. (C) CCR7 + T-cells from isolated CD4 + population in males, ** p 0.0063. (D) CD4 + cells gated for CD25 and/or CD44 in males. (E) Quantification of CD4 + T-cells from the CD3 + population from female mice, * p 0.0101. (F) CCR7 + T-cells from isolated CD4 + population in female mice, * p 0.0250. (G) CD4 + cells gated for CD25 and/or CD44 in female mice, ** p 0.0011. (H) Quantification of CD8 + T-cells from the CD3 + population from male mice. (I) CCR7 + T-cells from isolated CD8 + population in males, * p 0.0433. (J) CD8 + cells gated for CD25 and/or CD44 in males, * p 0.0396. (K) Quantification of CD8 + T-cells from the CD3 population from female mice, * p 0.041. (L) CCR7 + T-cells from isolated CD8 + population in female mice, ** p 0.0097. (M) CD8 + cells gated for CD25 and/or CD44 in female mice. All data are presented as mean +- standard error of the mean, n = 3 mice each for male/female WT vehicle-treated and WT paclitaxel groups, n = 4 mice each for male/female eIF4E S209A vehicle-trea
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Effect of BYBG on CD4+ T cells. CD4+ T cell concentrations were determined using peripheral blood mononuclear cells (PBMC) isolated from human whole blood samples. PBMCs were analyzed using flow cytometry to determine total ( A , CD3+/CD4+), T EM ( B , CCR7-/CD45RA-), and T CM ( C , CCR7+/CD45RA-) concentrations. Placebo (black bars) and BYBG (green bars) are represented separately and were statistically compared. Values represent the mean +- SEM. * indicates BYBG significantly different than placebo ( p < 0.05).
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Effect of BYBG on CD8+ T cells. CD8+ T cell concentrations were determined using peripheral blood mononuclear cells (PBMC) isolated from human whole blood samples. PBMCs were analyzed using flow cytometry to determine total ( A , CD3+/CD8+), T EM ( B , CCR7-/CD45RA-), and T CM ( C , CCR7+/CD45RA-), and T EMRA ( D , CCR7-/CD45RA+) concentrations. Placebo (black bars) and BYBG (green bars) are represented separately and were statistically compared. Values represent the mean +- SEM. * indicates BYBG significantly different than placebo ( p < 0.05).
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 HBV-related samples display higher proportion of effector/memory CD8+ T cells by flow cytometry assay. ( A ) Examples of CD3, CD4 and CCR7 staining to determine effector/memory CD4+ T cells. ( B ) Examples of CD3, CD8 and CCR7 staining to determine effector/memory CD8+ T cells. ( C ) The average proportion of effector/memory CD4+ T cells and CD8+ T cells in HBV and control groups (*p
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. Percentage of surface-stained cells presenting CD4+, CD8+, CCR7+, CD4+CCR7+, CD8+CCR7+, CD4+CD62L-, CD8+CD62L-, CD4+naive T cell, CD4+ effector memory T cell, CD4+ central memory T cells, CD8+ naive T cells, CD8+ effector memory T cells, and CD8+ central memory T cells in patients with AOSD, a patient with rheumatoid arthritis (RA), and a healthy control (HC). Results were obtained from 14 patients with AOSD, 20 RA patients, and 20 HCs. The horizontal line indicates the mean value for each group. The P value was determined by the Mann-Whitney U test.
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 BCA regulate MPhi polarization in vitro and in vivo . (A,B) Raw246.7 cells were treated with 4 mug/ml BCA for 2 h. Then, the cells were infected with Salmonella at MOI = 10:1 for 2 h. (A) The expression of surface markers (CCR7, CD86, CD163, and CD206) was determined by flow cytometry. The results are presented as MFI. (B) TNF-alpha and IL-10 in the supernatants were detected by ELISA. ** P < 0.01, *** P < 0.001. The data are representative of three experiments with similar results. (C,D) Mice were infected by intragastric administration of an overnight culture of Salmonella (10 5 bacteria in 0.1 ml PBS) through a gavage tube and then treated with 6.25 mg/kg BCA intragastrically by gavage daily (5 mice for each group). On the 5th day p.i., the mice were sacrificed and the peritoneal fluid was collected. (C) The expression of surface markers (CCR7, CD86, CD163, and CD206) in mouse peritoneal MPhis were determined by flow cytometry The results are presented as MFI. (D) TNF-alpha and IL-10 in ascitic fluid were detected by ELISA. * P < 0.05, ** P < 0.01, *** P < 0.001.
Conjugate: Yellow dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4. Transcriptomic Continuum between TIL and dLN Tumor-Reactive Cells (A) Violin plots of differentially expressed genes across TIL group I Th1 and dLN group IV Ccr7 + (clusters t1-2 and n5, respectively, as shown in Figure 1A ), as well as all other TIL and dLN populations. Unpaired t-test; ***p < 0.001. (B) Heatmap shows row-standardized expression of differentially expressed genes across dLN Ccr7 + clusters (group IV n5-6) and other dLN clusters (Treg and Tfh clusters n1 and n7-8, respectively). (C) Flow cytometry contour plots of Cxcr5 versus Ccr7 in Foxp3 - dLN cells (top). Overlaid protein expression of Bcl6 and CD200 in Ccr7 + and Cxcr5 + dLN cells and naive CD4 + splenocytes from tumor-free control mice (bottom). Data are representative of 17 mice analyzed in three experiments. (D) Flow cytometry contour plots of Cxcr5 versus PD-1 in dLN and Arm cells. Data are representative of 10 mice analyzed in two experiments. (E) Contour plot of dLN (red, clusters n7-8) and Arm (blue) Tfh cell distribution according to scRNA-seq-detected normalized expression of Icos versus Maf (top).Overlaid protein expression of ICOS in dLN and Arm PD-1 + Cxcr5 + (Tfh) cells and naive CD4 + splenocytes from tumor-free control mice (bottom). (F) Heatmap shows row-standardized expression of differentially expressed genes across TIL Isc and nRes clusters (as defined in the text, group II t3-4 and t5,respectively) and all other TIL clusters (Th1 and Treg clusters t1-2
Conjugate: Yellow dye